Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asunercept - Apogenix

Drug Profile

Asunercept - Apogenix

Alternative Names: APG-101; Apocept; Asinercept; CAN-008

Latest Information Update: 08 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apogenix
  • Developer Apogenix; CANbridge Pharmaceuticals; University Hospital Heidelberg
  • Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors; Fas ligand protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Glioblastoma; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma; Myelodysplastic syndromes

Highest Development Phases

  • Phase III COVID 2019 infections
  • Phase II Glioblastoma
  • No development reported Graft-versus-host disease; Myelodysplastic syndromes; Myocardial infarction; Solid tumours; Stroke

Most Recent Events

  • 18 Aug 2023 Apogenix terminates the phase III trial in COVID-2019 infections (Adjunctive treatment) in Austria, France, Georgia, Germany, India, Italy, Poland, South Africa, Spain due to lack of patients (IV) (NCT05639192)
  • 28 Mar 2023 NMPA grants Class 1 New Drug Designation to asunercept, prior to March 2023
  • 28 Mar 2023 CANbridge Pharmaceuticals completes enrolment in phase-II clinical trials in Glioblastoma (Combination therapy, Newly diagnosed) in China (IV) (NCT05447195)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top